Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:39 PM
Ignite Modification Date:
2025-12-24 @ 7:39 PM
NCT ID:
NCT04611503
Eligibility Criteria:
Inclusion Criteria:
* clinical diagnosis of retinitis pigmentosa
* confirmed mutation in PDE6A gene
* ≥ 18 years of age
* visual acuity ≥ 20/400
* no infection with Human Immundeficiency Virus (HIV)
* negative pregnancy test in women with childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential)
* Male patients must agree to use condoms during the first 6 months post treatment.
* Female patients of childbearing potential must agree to use an effective method of birth control during the first 6 months post treatment.
* ability to understand and willingness to consent to study protocol
Exclusion Criteria:
Ocular (study eye \& fellow eye)
* additional interfering ocular conditions with impact on study results (e.g. ocular opacity and advanced cataract, uveitis, amblyopia)
* recent (6 months) ocular surgery, intravitreal or subretinal implantation of a medical device
* disease causing mutations in another known retinitis pigmentosa gene
* ocular infection with herpes simplex virus in medical history
* history of ocular malignancies
* disorders of the internal retina (e.g. retinal detachment in the patients history)
* glaucoma defined as damage of the optic nerve
* vascular retinal occlusion
* diabetic patients suffering from retinopathy and/or macula edema
* any other retinopathy due to other diseases e.g. (but not limited to) arterial hypertension, trauma or acquired inflammatory diseases (uveitis serology), contraindication to pharmacological mydriasis (e.g. history of angle block glaucoma)
* absence of visual function on the contralateral eye Systemic
* systemic conditions (e.g. coronary heart disease, autoimmune disorders) which may affect study participation or outcome measures
* History of poorly controlled Diabetes Mellitus type 1 or type 2
* systemic illness or medically relevant abnormal laboratory values in blood analysis including renal and hepatic functions at inclusion
* patients treated with oral corticoids within 14 days prior inclusion
* current or recent participation in other study/or administration of biologic agent within the last three months
* known sensitivity to any compound used in the study
* contraindications to systemic immunosuppression
* contraindications in view of the planned surgery (e.g. but not limited to anaemia Hb\<10g/dl, coagulopathy with PT/PTT \>1,5 fold upper limit, hypertension with values above 180 mmHg systolic and 110 mmHg diastolic) including intolerance and contraindications to general anaesthesia
* intolerance to contrast agents used for diagnostic methods like angiography with fluoresceine or indocyanine green (e.g. but not limited to hyperthyroidism, hepatic insufficiency)
* subject/partner of childbearing potential unwilling to use adequate contraception for four months
* nursing or pregnant women
* any other cause that, in the investigator's opinion, renders potential subjects not suitable for the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04611503
Study Brief:
Protocol Section:
NCT04611503